Pooja M Dhupkar

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Osteosarcoma (OS) is a primary bone malignancy, commonly culminating into aggressive pulmonary metastasis. Despite chemotherapy advances, the 5-year survival of pulmonary metastatic OS remains 25-30%. Immunother-apy is one of the promising novel approaches to target minimal residual and relapsed disease. Previously, we have demonstrated that Liposomal(More)
  • 1